SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up on January 16th 2026 in the lawsuit that was filed for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE).
Investors, who purchased between November 4, 2024 and October 3, 2025 in excess of $100,000 in shares of Skye Bioscience, Inc. (NASDAQ: SKYE), have certain options and there are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On November 17, 2025, an investor in NASDAQ: SKYE shares filed a lawsuit over alleged securities laws violations by Skye Bioscience, Inc. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that nimacimab was less effective than Defendants had led investors to believe, that accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated, and that as a result, Defendants' public statements were materially false and misleading at all relevant times.
Those who purchased Skye Bioscience, Inc. (NASDAQ: SKYE) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
